27 - 29 February, 2012, Meliá Berlin Hotel, Germany
Get the latest news on our events , additional download possibilities, early bird deadlines and much more!
Download the Brochure
Click Here For Download Centre
Become a Pharma IQ Member and receive our weekly newsletter!
Connect to a global Pharma IQ social network
Learn more about sponsor & exhibit opportunities
For further information please contact us on:
+49 (0)30 20913 274 or via email: firstname.lastname@example.org
Mark Your Calendar
Tell a Colleague
Drug transporters – from in-vitro methods to brain penetrationNew FDA safety guidelines concerning active drug transporters will be released within the coming months. Get updates on new regulatory requirements at IQPC’s 3rd International Conference on Clinically Relevant Drug Transporters, 27 – 29 February 2012 in Berlin. Meet leading scientists from major pharmaceutical companies and research institutes to discover for example the impact of drug transporters on drug-drug interaction and much more.
Clinically Relevant Drug Transporters : A SynopsisDrug disposition in one’s system is effected by expression of Drug transporters in various tissues of the body. Development of drugs along with suitable pharmacokinetic profiles can take place by effective regulation of functionalities within Drug transporters. Enhancing of pharmacokinetic properties of a drug during pre-clinical stages of its development has gained acceptance in recent times. Accessing transporter activity through either computational or screening systems is considered to be effective tools for drug development. Functional genetic polymorphisms combined with drug-drug interactions involving drug transporters commands a necessary description. However, predicting pharmacokinetic changes caused by drug-drug interactions along with pharmacokinetic differences via transporter polymorphisms would add a quantitative value to the whole process. By Preeti Taluja,
Clinically relevant drug transporters: What progress is to be expected in 2012?Research into drug transporters forms an increasingly important part of the non-clinical development phase, with new fields such as pharmacogenomics offering new approaches to an area that is increasingly under the microscope of regulatory agencies.
Drug transporters and their role in drug interactions and toxicityA range of various drug transporters is present in the human body. Most important of these include transporters expressed particularly in the endothelium of the blood–brain barrier and in the epithelia of the liver, intestine, and kidney during drug development. These drug transporters are specific to their substrates.
Improving drug development programmes: Using efficient testing and modeling methods for drug transporter activityDrug transporters are one of the major determinants responsible for the pharmacokinetics, safety, and efficacy of various drugs. This fact presents a number of issues for the drug development process that may include all the transporters that are important in the absorption, distribution, metabolism, and excretion (ADME) of drugs, and what in vitro methods should be employed for studying the interactions of drugs with these transporters.
What are the advantages and disadvantages of HEK cells for the analysis of uptake transporters?Read here the transcript of the podcast interview with Dr Jörg König from the Institute for Experimental and Clinical Pharmacology and Clinical Toxicology at Friedrich-Alexander-University Erlangen-Nürnberg, Germany, on the analysis of transporter-mediated drug-drug interactions, different kinds of transporter-mediated drug-drug interactions, and the transferability of in vitro generated transport and inhibition data to the in vivo situation (IVIVE).
[ Register Now ]